Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2008

Open Access 01-10-2008 | Research article

Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1

Authors: Hans Neubauer, Susan E Clare, Wojciech Wozny, Gerhard P Schwall, Slobodan Poznanović, Werner Stegmann, Ulrich Vogel, Karl Sotlar, Diethelm Wallwiener, Raffael Kurek, Tanja Fehm, Michael A Cahill

Published in: Breast Cancer Research | Issue 5/2008

Login to get access

Abstract

Introduction

Breast tumors lacking the estrogen receptor-α (ER-α) have increased incidence of resistance to therapy and poorer clinical prognosis.

Methods

Whole tissue sections from 16 cryopreserved breast cancer tumors that were either positive or negative for the ER (eight ER positive and eight ER negative) were differentially analyzed by multiplex imaging of two-dimensional PAGE gels using 54 cm isoelectric focusing. Differentially detected spots of Progesterone Receptor Membrane Component 1 (PGRMC1) were shown to differ in phosphorylation status by differential two dimensional polyacrylamide gel electrophoresis of phosphatase-treated tumor proteins. Site directed mutagenesis was used to create putative phosphorylation site point mutants in PGRMC1. Stable transfectants of these mutants in MCF7 cells were assayed for their survival after oxidative stress, and for AKT kinase phosphorylation. Immune fluorescence using anti-PGRMC1 monoclonal antibody 5G7 was performed on breast cancer tissue microarrays.

Results

Proteins significantly differentially abundant between estrogen receptor negative and estrogen receptor positive tumors at the 0.1% level were consistent with published profiles, suggesting an altered keratin pool, and increased inflammation and wound responses in estrogen receptor negative tumors. Two of three spots of PGRMC1 were more abundant in estrogen receptor negative tumors. Phosphatase treatment of breast tumor proteins indicated that the PGRMC1 isoforms differed in their phosphorylation status. Simultaneous mutation of PGRMC1 serine-56 and serine-181 fully abrogated the sensitivity of stably transfected MCF7 breast cancer cells to peroxide-induced cell death. Immune fluorescence revealed that PGRMC1 was primarily expressed in ER-negative basal epithelial cells of mammary ductules. Even in advanced tumors, high levels of ER or PGRMC1 were almost mutually exclusive in individual cells. In five out of five examined ductal in situ breast cancers of comedo type, PGRMC1 was expressed in glucose transporter 1 negative or positive poorly oxygenated cells surrounding the necrotic core, surrounded by a more distal halo of ER-positive cells.

Conclusions

PGRMC1 phosphorylation may be involved in the clinical differences that underpin breast tumors of differing ER status.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
2.
Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001, 30: 62-66.CrossRef
3.
Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998, 51: 227-238. 10.1023/A:1006132427948.CrossRefPubMed
4.
Henderson IC: Risk factors for breast cancer development. Cancer. 1993, 71: 2127-2140. 10.1002/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2.CrossRefPubMed
5.
Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer. 2000, 89: 817-825. 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6.CrossRefPubMed
6.
McKeage K, Curran MP, Plosker GL: Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs. 2004, 64: 633-648. 10.2165/00003495-200464060-00009.CrossRefPubMed
7.
Platet N, Prevostel C, Derocq D, Joubert D, Rochefort H, Garcia M: Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer. 1998, 75: 750-756. 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A.CrossRefPubMed
8.
Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992, 150: 534-544. 10.1002/jcp.1041500314.CrossRefPubMed
9.
Fuqua SA, Cui Y: Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat. 2004, 87 (suppl 1): S3-10. 10.1007/s10549-004-1577-4.CrossRefPubMed
10.
Price JE, Polyzos A, Zhang RD, Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990, 50: 717-721.PubMed
11.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn van de M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
12.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
13.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004, 203: 661-671. 10.1002/path.1559.CrossRefPubMed
14.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn van de M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed
15.
Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA. 2003, 100: 15901-15905. 10.1073/pnas.2634067100.CrossRefPubMedPubMedCentral
16.
Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315: 1650-1659.CrossRefPubMed
17.
Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, Rijn van de M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2: E7-10.1371/journal.pbio.0020007.CrossRefPubMedPubMedCentral
18.
Poznanovic S, Wozny W, Schwall GP, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Buchner A, Gangnus R, Burgemeister R, Cahill MA: Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels. J Proteome Res. 2005, 4: 2117-2125. 10.1021/pr050218q.CrossRefPubMed
19.
Neubauer H, Clare SE, Kurek R, Fehm T, Wallwiener D, Sotlar K, Nordheim A, Wozny W, Schwall GP, Poznanoviæ S, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Cahill MA: Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis. 2006, 27: 1840-1852. 10.1002/elps.200500739.CrossRefPubMed
20.
Cahill MA: Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol. 2007, 105: 16-36. 10.1016/j.jsbmb.2007.02.002.CrossRefPubMed
21.
Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999, 20: 3551-3567. 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2.CrossRefPubMed
22.
Hand RA, Craven RJ: Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem. 2003, 90: 534-547. 10.1002/jcb.10648.CrossRefPubMed
23.
Perou CM, Sørlie T, Eisen MB, Rijn van de M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
24.
van 't Veer LJ, Dai H, Vijver van de MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy van der K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRefPubMed
25.
Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001, 61: 5979-5984.PubMed
26.
Velardo MJ, Burger C, Williams PR, Baker HV, Lopez MC, Mareci TH, White TE, Muzyczka N, Reier PJ: Patterns of gene expression reveal a temporally orchestrated wound healing response in the injured spinal cord. J Neurosci. 2004, 24: 8562-8576. 10.1523/JNEUROSCI.3316-04.2004.CrossRefPubMed
27.
Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005, 65: 2170-2178. 10.1158/0008-5472.CAN-04-4115.CrossRefPubMed
28.
Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, Rijn van de M, Brown PO, Vijver van de MJ: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005, 102: 3738-3743. 10.1073/pnas.0409462102.CrossRefPubMedPubMedCentral
29.
Kang SK, So HH, Moon YS, Kim CH: Proteomic analysis of injured spinal cord tissue proteins using 2-DE and MALDI-TOF MS. Proteomics. 2006, 6: 2797-2812. 10.1002/pmic.200500621.CrossRefPubMed
30.
Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen J, Li J, Cohn MA, Cantley LC, Gygi SP: Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA. 2004, 101: 12130-12135. 10.1073/pnas.0404720101.CrossRefPubMedPubMedCentral
31.
Sauer G, Korner R, Hanisch A, Ries A, Nigg EA, Sillje HH: Proteome analysis of the human mitotic spindle. Mol Cell Proteomics. 2005, 4: 35-43.CrossRefPubMed
32.
Suchanek M, Radzikowska A, Thiele C: Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells. Nat Methods. 2005, 2: 261-267. 10.1038/nmeth752.CrossRefPubMed
33.
Airley RE, Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007, 53: 233-256. 10.1159/000104457.CrossRefPubMed
34.
Crudden G, Loesel R, Craven RJ: Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol. 2005, 26: 142-146. 10.1159/000086485.CrossRefPubMed
35.
Hughes AL, Powell DW, Bard M, Eckstein J, Barbuch R, Link AJ, Espenshade PJ: Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 2007, 5: 143-149. 10.1016/j.cmet.2006.12.009.CrossRefPubMed
36.
Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, DeBose-Boyd RA: Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem. 2003, 278: 52479-52490. 10.1074/jbc.M310053200.CrossRefPubMed
37.
Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL: Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell. 2002, 10: 237-245. 10.1016/S1097-2765(02)00591-9.CrossRefPubMed
38.
Celis JE, Gromov P, Moreira JM, Cabezon T, Friis E, Vejborg IM, Proess G, Rank F, Gromova I: Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol Cell Proteomics. 2006, 5: 462-483.CrossRefPubMed
39.
Rae FK, Martinez G, Gillinder KR, Smith A, Shooter G, Forrest AR, Grimmond SM, Little MH: Analysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1. Oncogene. 2004, 23: 3067-3079. 10.1038/sj.onc.1207360.CrossRefPubMed
40.
Wagner KD, Wagner N, Wellmann S, Schley G, Bondke A, Theres H, Scholz H: Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). Faseb J. 2003, 17: 1364-1366.PubMed
41.
Helczynska K, Kronblad A, Jogi A, Nilsson E, Beckman S, Landberg G, Pahlman S: Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 2003, 63: 1441-1444.PubMed
42.
Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW: Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 2002, 16: 693-706. 10.1101/gad.952602.CrossRefPubMedPubMedCentral
43.
Swiatek-De Lange M, Stampfl A, Hauck SM, Zischka H, Gloeckner CJ, Deeg CA, Ueffing M: Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells. Glia. 2007, 55: 1061-1073. 10.1002/glia.20523.CrossRefPubMed
44.
Lee JN, Song B, DeBose-Boyd RA, Ye J: Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78. J Biol Chem. 2006, 281: 39308-39315. 10.1074/jbc.M608999200.CrossRefPubMed
45.
Song BL, DeBose-Boyd RA: Ubiquitination of 3-hydroxy-3-methylglutaryl-CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase. J Biol Chem. 2004, 279: 28798-28806. 10.1074/jbc.M402442200.CrossRefPubMed
46.
Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O'Hare MJ: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA. 1999, 96: 12589-12594. 10.1073/pnas.96.22.12589.CrossRefPubMedPubMedCentral
47.
Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004, 4: 665-676. 10.1038/nrc1431.CrossRefPubMed
48.
Chu PG, Weiss LM: Keratin expression in human tissues and neoplasms. Histopathology. 2002, 40: 403-439. 10.1046/j.1365-2559.2002.01387.x.CrossRefPubMed
49.
Boecker W, Buerger H: Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 2003, 36 (suppl 1): 73-84. 10.1046/j.1365-2184.36.s.1.7.x.CrossRefPubMed
50.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355: 560-569. 10.1056/NEJMoa052933.CrossRefPubMed
51.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1: 27-31. 10.1038/nm0195-27.CrossRefPubMed
52.
Garvin S, Nilsson UW, Dabrosin C: Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer. 2005, 93: 1005-1010. 10.1038/sj.bjc.6602824.CrossRefPubMedPubMedCentral
53.
Ardelt AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, Hurn PD: Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor-alpha in a rodent experimental stroke model. Stroke. 2005, 36: 337-341. 10.1161/01.STR.0000153795.38388.72.CrossRefPubMed
54.
Gerner C, Steinkellner W, Holzmann K, Gsur A, Grimm R, Ensinger C, Obrist P, Sauermann G: Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb Haemost. 2001, 85: 494-501.PubMed
55.
Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM: Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987, 57: 673-686.PubMed
56.
Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000, 96: 3302-3309.PubMed
57.
Moroz OV, Murzin AG, Makarova KS, Koonin EV, Wilson KS, Galperin MY: Dimeric dUTPases, HisE, and MazG belong to a new superfamily of all-alpha NTP pyrophosphohydrolases with potential 'house-cleaning' functions. J Mol Biol. 2005, 347: 243-255. 10.1016/j.jmb.2005.01.030.CrossRefPubMed
58.
Peluso JJ, Pappalardo A, Losel R, Wehling M: Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability. Biol Reprod. 2005, 73: 261-270. 10.1095/biolreprod.105.041061.CrossRefPubMed
59.
Engmann L, Losel R, Wehling M, Peluso JJ: Progesterone regulation of human granulosa/luteal cell viability by an RU486-independent mechanism. J Clin Endocrinol Metab. 2006, 91: 4962-4968. 10.1210/jc.2006-1128.CrossRefPubMed
60.
Lemos TA, Passos DO, Nery FC, Kobarg J: Characterization of a new family of proteins that interact with the C-terminal region of the chromatin-remodeling factor CHD-3. FEBS Lett. 2003, 533: 14-20. 10.1016/S0014-5793(02)03737-7.CrossRefPubMed
61.
Zhang H, Stephens LC, Kumar R: Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006, 12: 1479-1486. 10.1158/1078-0432.CCR-05-1519.CrossRefPubMed
62.
Leader JE, Wang C, Popov VM, Fu M, Pestell RG: Epigenetics and the estrogen receptor. Ann N Y Acad Sci. 2006, 1089: 73-87. 10.1196/annals.1386.047.CrossRefPubMed
63.
Nguyen A, Cai H: Netrin-1 induces angiogenesis via a DCC-dependent ERK1/2-eNOS feed-forward mechanism. Proc Natl Acad Sci USA. 2006, 103: 6530-6535. 10.1073/pnas.0511011103.CrossRefPubMedPubMedCentral
64.
Runko E, Kaprielian Z: Caenorhabditis elegans VEM-1, a novel membrane protein, regulates the guidance of ventral nerve cord-associated axons. J Neurosci. 2004, 24: 9015-9026. 10.1523/JNEUROSCI.2385-04.2004.CrossRefPubMed
65.
Mehlen P, Furne C: Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cell Mol Life Sci. 2005, 62: 2599-2616. 10.1007/s00018-005-5191-3.CrossRefPubMed
66.
Bouchard JF, Moore SW, Tritsch NX, Roux PP, Shekarabi M, Barker PA, Kennedy TE: Protein kinase A activation promotes plasma membrane insertion of DCC from an intracellular pool: a novel mechanism regulating commissural axon extension. J Neurosci. 2004, 24: 3040-3050. 10.1523/JNEUROSCI.4934-03.2004.CrossRefPubMed
67.
Krauss RS, Cole F, Gaio U, Takaesu G, Zhang W, Kang JS: Close encounters: regulation of vertebrate skeletal myogenesis by cell-cell contact. J Cell Sci. 2005, 118: 2355-2362. 10.1242/jcs.02397.CrossRefPubMed
68.
Nikolopoulos SN, Giancotti FG: Netrin-integrin signaling in epithelial morphogenesis, axon guidance and vascular patterning. Cell Cycle. 2005, 4: e131-135.CrossRefPubMed
69.
Slorach EM, Werb Z: Epithelial morphogenesis: Netrin comes to a sticky and terminal end. Curr Biol. 2003, 13: R491-493. 10.1016/S0960-9822(03)00411-1.CrossRefPubMed
70.
Strizzi L, Bianco C, Raafat A, Abdallah W, Chang C, Raafat D, Hirota M, Hamada S, Sun Y, Normanno N, Callahan R, Hinck L, Salomon D: Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. J Cell Sci. 2005, 118: 4633-4643. 10.1242/jcs.02574.CrossRefPubMed
71.
Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005, 17: 548-558. 10.1016/j.ceb.2005.08.001.CrossRefPubMed
Metadata
Title
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
Authors
Hans Neubauer
Susan E Clare
Wojciech Wozny
Gerhard P Schwall
Slobodan Poznanović
Werner Stegmann
Ulrich Vogel
Karl Sotlar
Diethelm Wallwiener
Raffael Kurek
Tanja Fehm
Michael A Cahill
Publication date
01-10-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2155

Other articles of this Issue 5/2008

Breast Cancer Research 5/2008 Go to the issue

Research article

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer

Editorial

Breast cancer stem cell markers – the rocky road to clinical applications

Research article

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients

Research article

ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients

Research article

Targeting aspartate aminotransferase in breast cancer

Research article

A candidate molecular signature associated with tamoxifen failure in primary breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits